been proposed, including changes in diet, sunlight, reproductive and gynaecological factors, use of oestrogens and sedatives, and increased life expectancy.
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All these, however, need to account for the parallel changes in men and women and the worldwide increase in incidence. Although several factors may have operated the most likely single factor is change in activity. Physical activity is related to both bone density and the risk of the elderly falling. Disuse is strongly related to rapid bone loss in most age groups. Moreover, musculoskeletal strength related to activity is probably the most important factor influencing hip fractures in the over 75s, among whom most such fractures occur.4
The only major study showing a levelling off of the incidence of hip fracture showed a fall in the rate of increase in women in Rochester, Minnesota, in the mid-1950s.' Rates in men continued to rise, and the authors were unable to explain these findings on the basis of environmental factors. Possible reasons for the changes in the United Kingdom remain speculative. In most developed countries since the second world war work has become less physically arduous and people walk less. Increases in social services, transport, and retirement homes may have reduced physical activity in the elderly. The age at which activity has a maximal beneficial effect is uncertain. Our data might be explained by activity having fallen dramatically from the 1950s to the 1970s and then stabilised either in middle life or in old age; alternatively, there may be a threshold beyond which a further reduction in activity has no added effect on skeletal state. Further work is needed to confirm these findings and to understand the mechanisms entailed. 
myocardium, or interferon may induce coronary spasm. Since the effect of interferon was reversible in our patient we suggest that cardiomyopathy was induced through impaired myocyte metabolism rather than through histological damage.
Our patient's dramatic improvement could not have been due to drug treatment alone because diuretics do not greatly improve ventricular function, and most of his drugs had been stopped. It seems, therefore, that in the absence of pre-existing heart disease withdrawing interferon leads to cardiac function returning to normal.
A report has now appeared on reversible cardiac dysfunction associated with interferon treatment in a patient with AIDS.4 The potential cardiotoxicity of interferon was attributed to a synergistic interaction with HIV infection. Our case suggests that other mechanisms are responsible for the cardiotoxic effect of interferon. Case reports During the 12 months September 1988 to August 1989, 229 patients with falciparum malaria were seen at this hospital. Five were not cured by treatment with quinine followed by one dose of pyrimethaminesulfadoxine (table) . Four of these patients received treatment in hospital; one (case 4) took her last few days' treatment with quinine and the pyrimethaminesulfadoxine at home. Blood films obtained at the end of the regimen were negative for parasites in cases 1, 2, 4, and 5; in case 3 the film showed scanty trophozoites on the day of discharge. The patients stayed in the United Kingdom throughout the study, and none had any medical condition that might impair the response to treatment.
Recrudescences occurred 17-77 days after the regimen was started; each blood film was examined by several experienced observers to confirm the finding of Details offive patients who developed recrudescence offalcipanrm malaria after treatment with quinine and pyrimethamine-sulfadoxine (Fansidar) *A course of quinine was given orally (except in cases 2 and 4, in which the first two and first four doses, respectively, were given intravenously) and was followed by three tablets (total 75 mg pyrimethamine, 1-5 g sulfadoxine) of Fansidar (except in case 4, in which only one tablet was given).
tMefloquine 750 mg was given on two occasions 12 hours apart (except in case 4, in which 250 mg was given twice).
parasites. All patients subsequently responded to mefloquine or quinine followed by mefloquine. One (case 2) developed a self limiting anxiety state 48 hours after taking mefloquine.
Comment
The development of resistance to a regimen comprising quinine and pyrimethamine-sulfadoxine is worrying. So far this resistance has presented as an initial clearance of the parasitaemia and clinical resolution followed by relapse and has been described in Thailand and east Africa.' 2 Three of the five patients reported on here contracted their disease in west Africa. We believe that these are the first cases of malaria resistant to quinine and pyrimethaminesulfadoxine from that region to be described.
In 
